Regarding transcript expression levels in AAA tissue of RNase A- and PBS-treated animals at the experimental end point, our analysis was limited by the circumstance that many of the investigated genes, including SMA/ACTA2, CCL2, CD68, and MMP2 exhibited peak expression changes on day 8 before treatment start but had largely returned to baseline by day 28 in control mice, leaving a small window of detection for therapeutic impact. This evidence concerns the gene RNASE1 and triple-A syndrome.